Please login to the form below

Not currently logged in
Email:
Password:

rFIXFc

This page shows the latest rFIXFc news and features for those working in and with pharma, biotech and healthcare.

FDA starts review of Biogen Idec's haemophilia A therapy

FDA starts review of Biogen Idec's haemophilia A therapy

Eloctate was developed in partnership with Swedish Orphan Biovitrum (Sobi), which also collaborated on the development of Biogen Idec's haemophilia B candidate Alprolix (recombinant factor IX Fc fusion protein; rFIXFc).

Latest news

  • Biogen submits haemophilia drug for US approval Biogen submits haemophilia drug for US approval

    Backing the submission of rFIXFc are results from B-LONG, which Biogen says is the largest phase III clinical study in haemophilia B to date. ... This study demonstrated that rFIXFc was both clinically effective and safe, helping to prevent bleeding

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics